nach oben

Clinical Pharmacokinetics

Erschienen in:

01.03.2015 | Letter to the Editor

Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure

verfasst von: Sylvain Goutelle, Michel Tod

Erschienen in: Clinical Pharmacokinetics | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Excerpt

We read with interest the article by Chang and colleagues who studied the influence of cytochrome P450 2C19 (CYP2C19) genetic polymorphism on citalopram and escitalopram exposure by using meta-analysis [1]. The authors state that this is the first study which provides precise estimates of the influence of CYP2C19 genotypes on (es)citalopram drug exposure, especially for heterozygous genotypes with the CYP2C19*17 gain-of-function allele. …

Chang M, Tybring G, Dahl ML, Lindh JD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014;53(9):801–11.CrossRefPubMed

Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, Tod M. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J. 2013;15(2):415–26.CrossRefPubMedCentralPubMed

Tod M, Goutelle S, Gagnieu MC. Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6. Clin Pharmacol Ther. 2011;90(4):582–7.CrossRefPubMed

Castellan AC, Tod M, Gueyffier F, Audars M, Cambriels F, Kassai B, et al. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure. Clin Pharmacokinet. 2013;52(3):199–209.CrossRefPubMed

Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196–204.CrossRefPubMed

Tod M, Nkoud-Mongo C, Gueyffier F. Impact of genetic polymorphism on drug–drug interactions mediated by cytochromes: a general approach. AAPS J. 2013;15(4):1242–52.CrossRefPubMedCentralPubMed

Titel: Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure
verfasst von: Sylvain Goutelle
Michel Tod
Publikationsdatum: 01.03.2015
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 3/2015
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-014-0217-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Drug Transporters in the Central Nervous System

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects

Efficacy of Tolvaptan Added to Furosemide in Heart Failure Patients with Advanced Kidney Dysfunction: A Pharmacokinetic and Pharmacodynamic Study

Interethnic Differences in Pharmacokinetics of Antibacterials

Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure: Authors’ Reply

A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation